The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 47 | 17.3x | 20.1x | Near average | |
Growth | 58 | 11.7% | 5.6% | Near average | |
Quality | 87 | 87.8% | 7.6% | Above average | |
Safety | 91 | -2.3x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Catalyst Pharmaceuticals, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Catalyst Pharmaceuticals, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
CPRX stock has experienced a negative shift in analyst sentiment over the past 30 days, with the average price target being lowered from 32 to 31.75 dollars. This change, although numerically small, reflects a decline in confidence driven by a series of Downgrades by major institutions such as H.C. Wainwright, Citigroup, and Oppenheimer, who moved from a Buy recommendation to Neutral.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.